Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

Clinical Gastroenterology and Hepatology

Volumn 16, Issue 9, 2018, Pages 1374-1384

  Hirten, Robert P ^a   Iacucci, Marietta ^b   Shah, Shailja ^c   Ghosh, Subrata ^b   Colombel, Jean Frederic ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biologics; Crohn's Disease; Inflammatory Bowel Disease; Ulcerative Colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; ATACICEPT; B7 ANTIGEN; BIOLOGICAL PRODUCT; CD28 ANTIGEN; COTRIMOXAZOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

BIOLOGICAL THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GASTROENTEROLOGIST; GRANULOMATOSIS; HUMAN; IMMUNE MEDIATED INJURY; INFLAMMATORY BOWEL DISEASE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE ACTIVATION; PNEUMOCYSTIS PNEUMONIA; REMISSION; REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEGENER GRANULOMATOSIS; ADVERSE DRUG REACTION; ADVERSE EVENT; COMBINATION DRUG THERAPY; PROCEDURES; PSORIASIS; RHEUMATOID ARTHRITIS; SCLERITIS;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PSORIASIS; SCLERITIS; TREATMENT OUTCOME;

EID: 85048863578     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.02.024     Document Type: Review

References (47)

1. Reinink, A.R., Lee, T.C., Higgins, P.D., Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis 22 (2016), 1859–1869.
2. Cote-Daigneault, J., Bouin, M., Lahaie, R., et al. Biologics in inflammatory bowel disease: What are the data?. United European Gastroenterol J 3 (2015), 419–428.
3. Peyrin-Biroulet, L., Lemann, M., Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 33 (2011), 870–879.
4. Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
5. Baert, F., Noman, M., Vermeire, S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003), 601–608.
6. Sands, B.E., Kozarek, R., Spainhour, J., et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 13 (2007), 2–11.
7. Hirten, R., Longman, R.S., Bosworth, B.P., et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease. Am J Gastroenterol 110 (2015), 1737–1738.
8. Bethge, J., Meffert, S., Ellrichmann, M., et al. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterol, 4, 2017, e000127.
9. Yzet, C., Dupas, J.L., Fumery, M., Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease. Am J Gastroenterol 111 (2016), 748–749.
10. Cuchacovich, R., Garcia-Valladares, I., Espinoza, L.R., Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol 39 (2012), 187–193.
11. Babalola, O., Lakdawala, N., Strober, B.E., Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report. JAAD Case Rep 1 (2015), 3–4.
12. Heinecke, G.M., Luber, A.J., Levitt, J.O., et al. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol 12 (2013), 1098–1102.
13. Gniadecki, R., Bang, B., Sand, C., Combination of antitumour necrosis factor-alpha and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study. Br J Dermatol 174 (2016), 1145–1146.
14. Papp, K.A., Miller, B., Gordon, K.B., et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006), S164–S170.
15. Adisen, E., Karaca, F., Gurer, M.A., When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin Exp Dermatol 33 (2008), 164–166.
16. Kitamura, G., Mehr, N., Anderson, N., et al. A case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J, 15, 2009, 11.
17. Hamilton, T.K., Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J Drugs Dermatol 7 (2008), 1089–1093.
18. Krueger, G.G., Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 22 (2004), 407–426, viii.
19. Krell, J.M., Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol 54 (2006), 1099–1101.
20. Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343 (2000), 1594–1602.
21. Sheehy, C., Murphy, E., Barry, M., Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-b27-associated arthropathy. Rheumatology (Oxford) 45 (2006), 1314–1315.
22. Scallon, B., Cai, A., Solowski, N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002), 418–426.
23. Mpofu, S., Fatima, F., Moots, R.J., Anti-TNF-alpha therapies: they are all the same (aren't they?). Rheumatology (Oxford) 44 (2005), 271–273.
24. Weinblatt, M., Schiff, M., Goldman, A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66 (2007), 228–234.
25. Cohen, S., Hurd, E., Cush, J., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002), 614–624.
26. Genovese, M.C., Cohen, S., Moreland, L., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004), 1412–1419.
27. Gorman, S.D., Clark, M.R., Routledge, E.G., et al. Reshaping a therapeutic CD4 antibody. Proc Natl Acad Sci U S A 88 (1991), 4181–4185.
28. Morgan, A.W., Hale, G., Rebello, P.R., et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM 101 (2008), 299–306.
29. Smolen, J.S., Keystone, E.C., Emery, P., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007), 143–150.
30. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006), 1390–1400.
31. Emery, P., Deodhar, A., Rigby, W.F., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (study evaluating rituximab's efficacy in MTX inadequate responders (SERENE)). Ann Rheum Dis 69 (2010), 1629–1635.
32. Koumakis, E., Wipff, J., Avouac, J., et al. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents. J Rheumatol 36 (2009), 2125–2126.
33. Feuchtenberger, M., Kneitz, C., Roll, P., et al. Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after TNF failure: Case report. Open Rheumatol J 3 (2009), 9–13.
34. Blank, N., Max, R., Schiller, M., et al. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Rheumatology (Oxford) 48 (2009), 440–441.
35. Cohen, S.B., Emery, P., Greenwald, M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
36. Rigby, W.F., Mease, P.J., Olech, E., et al. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. J Rheumatol 40 (2013), 599–604.
37. Greenwald, M.W., Shergy, W.J., Kaine, J.L., et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 63 (2011), 622–632.
38. van Vollenhoven, R.F., Wax, S., Li, Y., et al. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheumatol 67 (2015), 2828–2836.
39. Weinblatt, M., Combe, B., Covucci, A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006), 2807–2816.
40. Record, J.L., Beukelman, T., Cron, R.Q., Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 38 (2011), 180–181.
41. Morarji, J., Joshi, L., Tomkins-Netzer, O., et al. Combined infliximab and rituximab in necrotising scleritis. Case Rep Ophthalmol 3 (2012), 286–290.
42. Park, K.T., Colletti, R.B., Rubin, D.T., et al. Health insurance paid costs and drivers of costs for patients with Crohn's disease in the united states. Am J Gastroenterol 111 (2016), 15–23.
43. Pillai, N., Dusheiko, M., Burnand, B., et al. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One, 12, 2017, e0185500.
44. Tang, D.H., Harrington, A.R., Lee, J.K., et al. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflamm Bowel Dis 19 (2013), 2673–2694.
45. Marchetti, M., Liberato, N.L., Di Sabatino, A., et al. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ 14 (2013), 853–861.
46. Lindsay, J., Punekar, Y.S., Morris, J., et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease–modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 28 (2008), 76–87.
47. Bodger, K., Kikuchi, T., Hughes, D., Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 30 (2009), 265–274.